Zydus Wellness Ltd
₹488.80
-4.55 (0.92%)
Fri, 06 Nov 2026, 09:29 pm
Zydus Wellness News
Zydus Wellness Q2FY27: PAT up 53% YoY
Zydus Wellness reported a 53% YoY rise in standalone net profit to ₹116 million for Q2FY27. Consolidated profit surged to ₹51 million from a loss last year, driven by Comfort Click acquisition.
03 Nov 2026
companies
Zydus Wellness responds to FSSAI notice
Zydus Wellness received an FSSAI notice on September 24 and responded on October 4, asserting that its product-label claims are scientifically substantiated.
23 Oct 2026
companies
Zydus Wellness gets ESG rating of 72
Zydus Wellness Ltd received an overall ESG rating of 72 from NSE Sustainability Ratings for FY26. The score places the company in the 'leader' category, based on public domain data.
16 Oct 2026
companies
Zydus Wellness CMO Arjit Sengupta resigns
Arjit Sengupta has resigned as Chief Marketing Officer of Zydus Wellness effective September 18, 2026, citing personal reasons requiring relocation to Mumbai.
18 Sept 2026
companies
Zydus Wellness to host Q1FY27 earnings call on Aug 4
Zydus Wellness will hold an analyst call on August 4, 2026, to discuss unaudited Q1FY27 results. CEO Tarun Arora and CFO Umesh Parikh will represent the firm.
21 Jul 2026
companies
Market Current News
CONTINENTAL CONTROLS LTD.
Continental Controls rights issue oversubscribed
Continental Controls Limited completed its rights issue of 1.96 crore shares at ₹10 each. The issue was oversubscribed 112.75% and shares list on BSE on November 5, 2026.
05 Nov 2026
ipo
Jivial Industries Limited
Jivial Industries changes IPO machinery vendors
Jivial Industries Ltd approved partial vendor changes for three machinery sets in its IPO project. Costs and timelines remain unchanged despite the switch.
05 Nov 2026
ipo
Antala IPO Day 6: Subscribed 6.43x
Antala Industries IPO sees strong QIB demand at 66.72x on final day. Total subscription reaches 6.43x as Retail and NII interest picks up.
05 Nov 2026
ipo
IGL Spirits lists on BSE and NSE post-demerger
IGL Spirits Limited listed on BSE and NSE on November 4, 2026. The demerged entity reported FY26 revenue of ₹2,801 crore and EBITDA of ₹492 crore.
04 Nov 2026
ipo
Ennature Bio Pharma lists on NSE, BSE
Ennature Bio Pharma Limited listed on NSE and BSE on November 4, 2026. The biopharma division reported ₹246 crore revenue in FY26, driven by branded nutraceuticals.
04 Nov 2026
ipo